Popular Psoriasis News and Current Events | Page 13

Popular Psoriasis News and Current Events, Psoriasis News Articles.
Sort By: Most Relevant | Most Recent
Page 13 of 14 | 534 Results
Home UVB therapy for psoriasis as effective and safe as hospital treatment
For patients with psoriasis, treatment with ultraviolet B at home is as effective and as safe as conventional hospital based phototherapy, concludes a study published on bmj.com today. (2009-05-07)

New treatment for psoriasis is safe and effective
A new treatment for moderate to severe plaque psoriasis has proven safe and effective in a phase III trial. There is also an almost linear relationship between drug dose and response, suggesting that patients can be more accurately dosed to achieve a clinical response while minimizing the risk of side effects. These are the conclusions of authors of an article in this week's edition of the Lancet. (2008-04-17)

Long-term apremilast demonstrates continued efficacy in patients with psoriatic arthritis
New data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism show that apremilast administered to patients with psoriatic arthritis continues to demonstrate meaningful clinical responses beyond 24 weeks. For patients who completed 52 weeks of the study, up to 65 percent achieved ACR20 response rates. Also, apremilast continued to be well tolerated with an acceptable longer-term safety profile. (2013-06-12)

Alzheimer's disease in mice alleviated promising therapeutic approach for humans
Pathological changes typical of Alzheimer's disease were significantly reduced in mice by blockade of an immune system transmitter. A research team from Charité - Universitätsmedizin Berlin and the University of Zurich has just published a new therapeutic approach in fighting Alzheimer's disease in the current issue of Nature Medicine. This approach promises potential in prevention, as well as in cases where the disease has already set in. (2012-11-25)

M. D. Anderson researchers discover key protein in psoriasis
Researchers at The University of Texas M. D. Anderson Cancer Center simultaneously have resolved a controversy over the cause of psoriasis and developed the first mouse model that fully mimics the human disorder. What's more, the scientists have demonstrated they can block the signals that lead to psoriasis in their mouse model with a topical skin treatment that can prevent new outbreaks as well as treat existing psoriatic plaques. (2004-12-12)

Researchers uncover new genetic links to psoriasis
In a comprehensive study of the genetic basis of psoriasis, researchers at Washington University School of Medicine in St. Louis have discovered seven new sites of common DNA variation that increase the risk of this troublesome skin condition. They also found that variations in one genetic region link psoriasis and psoriatic arthritis to other autoimmune disorders. These results appear April 4 in the open-access journal PLoS Genetics. (2008-04-03)

Eczema patients lack natural antibiotic in skin
Patients with atopic dermatitis, or eczema, are susceptible to bacterial infections of their skin because they fail to produce two antimicrobial peptides. The findings demonstrate for the first time the clinical significance of these peptides in humans, and suggest that a medication containing or inducing the peptides may fight the infections that plague millions of atopic dermatitis patients. The accompanying editorial in the New England Journal of Medicine called it a (2002-10-09)

Indigo ointment may help treat patients with psoriasis
An ointment made from indigo naturalis, a dark blue plant-based powder used in traditional Chinese medicine, appears effective in treating plaque-type psoriasis, according to a report in the November issue of Archives of Dermatology, one of the JAMA/Archives journals. (2008-11-17)

Anti-inflammatory drug prevents liver cancer in at-risk liver patients
Colchicine, an anti-inflammatory drug most often used to treat gout, prevented liver cancer in patients with hepatitis virus-related end-stage liver disease, according to a new study. (2006-09-11)

Hypertension, antihypertension medication, risk of psoriasis
Women with long-term high blood pressure appear to be at an increased risk for the skin condition psoriasis, and long-term use of beta (β)-blocker medication to treat hypertension may also increase the risk of psoriasis. (2014-07-02)

Glucocorticoid plays key role in skin abnormalities induced by psychological stress
A new study shows how psychological stress induces abnormalities in skin structure and function that could initiate or worsen skin disorders such as psoriasis and atopic dermatitis. The study provides a link for understanding the roles psychological stress and glucocorticoid, a type of steroid, play in skin disorders and shows that blocking glucocorticoid can prevent skin abnormalities induced by psychological stress. (2006-12-01)

New STELARA data show inhibition of joint destruction in active psoriatic arthritis
New findings from two integrated Phase 3 Janssen Research & Development, LLC-sponsored studies showed treatment with STELARA (ustekinumab) resulted in significantly greater inhibition of structural damage in patients with active psoriatic arthritis compared with placebo. These results are being presented during the 2013 Annual Meeting of the American College of Rheumatology. (2013-10-28)

Phase 3 psoriatic arthritis data for ENBREL® (etanercept) announced at a national scientific meeting
Phase 3 results of ENBREL® (etanercept) studied in patients with psoriatic arthritis will be presented this week at the 65th Annual American College of Rheumatology National Scientific Meeting in San Francisco. These data are currently being reviewed by the FDA for potential approval of ENBREL for the treatment of psoriatic arthritis. (2001-11-12)

Shingles vaccine among patients with psoriasis, RA not linked with increased risk of shingles
Although some have suggested that patients receiving medication for immune-mediated diseases such as rheumatoid arthritis or psoriasis may be at increased risk of herpes zoster (HZ; shingles) shortly after receipt of the vaccine, an analysis that included nearly 20,000 vaccinated Medicare beneficiaries finds that the live zoster vaccine is not associated with an increased risk of HZ shortly after vaccination in patients currently treated with biologics (2012-07-03)

Smoking associated with severity of psoriasis
Cigarette smoking is associated with the clinical severity of the skin disease psoriasis, and both smoking and obesity are more prevalent among psoriasis patients, according to two studies in the December issue of Archives of Dermatology, one of the JAMA/Archives journals. (2005-12-19)

Multiple factors affect psoriasis treatment compliance
Psychological, social, and disease-related issues may influence a patient's compliance with psoriasis treatment, according to an article in the April issue of The Archives of Dermatology, one of the JAMA/Archives journals. (2004-04-19)

Drug breakthrough for psoriasis sufferers
An international team led by a dermatologist at The University of Manchester has found that treatment with the emerging drug infliximab, marketed as Remicade, can quickly and significantly improve psoriasis symptoms. (2005-10-13)

JCI online early table of contents: August 7, 2008
This release contains summaries, links to PDFs and contact information for the following newsworthy papers to be published online, August 7, 2008, in the JCI: Possible new treatment for psoriasis; Why gene therapy caused leukemia in some (2008-08-07)

Severe psoriasis associated with increased risk of death
Patients with severe psoriasis appear to have an increased risk of death compared with patients without the skin condition, according to a report in the December issue of Archives of Dermatology, one of the JAMA/Archives journals. (2007-12-17)

Certain biologic therapies for psoriasis do not appear to increase risk for cardiovascular problems
Although some preliminary reports have indicated an increased risk of major adverse cardiovascular events with the use of certain biologic therapies to treat chronic plaque psoriasis, an analysis of previous studies finds no significant difference in the rate of these events among patients who received these medications compared to patients who received placebo, according to an article in the Aug. 24/31 issue of JAMA. (2011-08-23)

Potential new treatment approach for severe asthma
Researchers have uncovered a potentially new treatment approach for severe asthma, by blocking a powerful immune system chemical, present in large amounts in patients with the severe form of the disease, a small study in Thorax reveals. (2005-09-14)

Jefferson scientists identify gene defect leading to abnormal skin development and cancer
Researchers at Jefferson Medical College and at the Wadsworth Center in New York have identified a gene defect in mice resulting in a range of abnormalities, from cyclical hair loss and skin cancer to severe problems in normal skin development. The work may lead to improved treatments for skin injuries, including burns, and might have implications for diseases such as eczema and psoriasis, as well as certain cancers. (2005-10-02)

Medicare patients have low adherence to biologic drug therapy for psoriasis
About half of Medicare patients who start taking biologic therapies for moderate to severe plaque psoriasis stop within a year, according to a new study. Previous studies have found similar results among the privately insured in the United States. The new study is the first to explore this issue among the elderly and disabled who are covered under Medicare. Lack of data in this population has been a major research gap, given that such patients are often underrepresented in clinical trials. (2016-04-25)

Einstein's Dr. Vern Schramm elected to the National Academy of Sciences
Vern L. Schramm, Ph.D., professor and Ruth Merns Chair of Biochemistry at the Albert Einstein College of Medicine of Yeshiva University, has been elected to the National Academy of Sciences, the nation's most prestigious honorary society for scientists. His election was announced today at the Academy's annual meeting in Washington, D.C. (2007-05-04)

GroPep news: Key psoriasis patent granted in Japan and new asthma patent filed for GroPep drug
Biopharmaceutical company GroPep Limited, (ASX: GRO) made two significant patent announcements today: (1) the granting in Japan of a key patent covering the active ingredient of its developmental psoriasis drug, PP0102. (2) the filing of an International Patent Application on the use of the same active ingredient for the treatment of asthma. The patent news represents a strengthening of GroPep's biopharmaceutical development program, with on going research into the highly profitable field of immune-based diseases. (2005-06-02)

Topical treatment for psoriasis targets deeper layers of the skin, improves healing
A novel combination anti-psoriasis therapy has potential for superior and longer-lasting therapeutic effects than current topical treatments by targeting genetic abnormalities in deeper layers of the skin. This research is being presented at the 2013 American Association of Pharmaceutical Scientists Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in San Antonio, Nov. 10-14. (2013-11-14)

Sanford-Burnham researchers identify new target to treat psoriasis
The study identifies the BTLA inhibitory receptor as the key factor in limiting inflammatory responses, particularly in skin. The study has important implications for developing drugs to treat psoriasis and potentially other inflammatory and autoimmune diseases. (2013-12-05)

NYU Langone Medical Center awarded NIH grants totaling $1,560,000
Two NYU Langone Medical Center researchers have received $1,560,000 in grant support for their first year of studies focused on microbiome and psoriasis and on microbiome and esophageal cancer from the National Institutes of Health. The studies being conducted at NYU Langone Medical Center are two of several projects being conducted through the NIH Roadmap for Medical Research as part of the Human Microbiome Project taking place at institutions across the country. (2009-06-24)

How testosterone protects against inflammation
Pharmacists of the University Jena and partners have shown that cells from men and women react in a different manner to inflammatory stimuli. They found that in male cells the enzyme phospholipase D is less active than in the female ones. Based on these findings, the Jena pharmacists concluded that the male sex hormones play a key role in the modulation of the immune response. (2011-07-26)

Children with eczema have the same impaired quality of life as those with kidney disease
Having a serious skin condition can cause a child as much distress as having a chronic illness such as epilepsy, renal disease or diabetes. Researchers compared the quality of life of 379 children with skin diseases with 161 children with chronic illnesses, The study appears in the latest British Journal of Dermatology. (2006-07-18)

Results from open-label Raptiva™ study suggest continued benefit with long-term treatment
Genentech and XOMA today announced preliminary results from an open-label, multicenter trial evaluating the long-term safety and tolerability of continuous RaptivaTM (efalizumab) treatment in patients with moderate-to-severe psoriasis. The data were presented on Saturday, March 22 at the 61st annual American Academy of Dermatology meeting being held in San Francisco. (2003-03-24)

Children with psoriasis may be at increased risk for overweight and obesity
A study of children in nine countries found that psoriasis in children was associated with an increased risk for overweight and obesity, regardless of psoriasis severity. (2012-11-19)

Boston University Medical Center researcher honored by the Institute for Functional Medicine
Michael F. Holick, PhD, MD, was recently awarded the 2007 Linus Pauling Functional Medicine Award from the Institute for Functional Medicine. Holick, an internationally recognized expert in vitamin D and skin research, received the award for decades of pioneering work that elucidated the important role vitamin D plays in a wide variety of chronic health conditions. The award was presented at the 14th International Symposium on Functional Medicine in Tuscon, Ariz. (2007-05-25)

The skin's acid coating: SFVAMC researchers explain its origin and how it maintains skin integrity
Acid on the skin might sound disturbing, but the mild acidity of the skin's surface actually helps to maintain the strength and cohesiveness of the skin. Now researchers at SFVAMC have discovered where this acidity comes from, and they suggest how it may help to hold the skin together. (2001-08-15)

Gene variation is 'major genetic determinant of psoriasis'
A specific genetic region that has been increasingly identified as the strongest genetic link to psoriasis has an even more significant role in the chronic skin disease than has been suspected, University of Utah medical researchers show in a new study. (2009-08-27)

Drug developed for rare disease may help millions more as treatment for cancer, autoimmune diseases
An anti-angiogenesis drug developed at the University of Michigan is showing promise in studies of three different disease families, including multiple forms of cancer. The drug, tetrathiomolybdate or TM, essentially wages war against copper, which serves to choke off tumor growth, fibrosis and inflammation. (2003-09-10)

Long-term etanercept treatment reduces psoriasis severity without increased adverse events
Extended exposure to the psoriasis medication etanercept does not appear to cause more infections or adverse events than placebo, and improvements in several measures of disease severity were observed for up to 96 weeks of therapy, according to a study in the June issue of Archives of Dermatology, one of the JAMA/Archives journals. (2007-06-18)

Study sheds light on genetic differences that cause a childhood eye disease
Medical researchers at the University of Alberta have unlocked part of the mystery underlying a childhood eye disease. New research shows how children with some types of glaucoma end up with missing or extra pieces of DNA. (2008-10-31)

GroPep to pursue promising asthma drug following preclinical study results
Adelaide biotechnology company GroPep has completed preclinical efficacy studies of its T-cell peptide drug candidate, in models of psoriasis and asthma. GroPep will undertake a market feasibility assessment for the use of the drug in asthma but will cease development for psoriasis. (2005-12-14)

Scientists discover cells that control inflammation in chronic disease
A new type of immune cell that can be out of control in certain chronic inflammatory diseases, worsening the symptoms of conditions like psoriasis and asthma, is described for the first time this week in the Journal of Clinical Investigation. (2009-11-17)

Page 13 of 14 | 534 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.